Alliance Activity Remained Strong in the Life Sciences Industry with 402 Alliances Forged During the Second Quarter of 2005.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c32213) has announced the addition of Life Sciences Industry: Quarterly Deal Review - Second Quarter 2005 to their offering

The second quarter of 2005 proved both promising and foreboding for the life sciences industry. On one hand, life sciences securities, notably biotechnology companies, experienced a sharp rebound from their first quarter drop. Other important financial instruments, such as debt financing and private placements, demonstrated their vitality during the second quarter. At the same time, only two IPOs were issued on the U.S. market, indicating that the financial environment was not as welcoming as it had been in the previous seven quarters.

Foreign IPOs outnumbered U.S. offerings for the second quarter in a row. SPOs also suffered during the quarter, with only eight offerings. Ownership activity diminished during the second quarter and did not include a megamerger; the largest deal of the quarter was Fresenius Medical Care's definitive agreement to purchase Renal Care Group for $3.5 billion. However, alliance activity remained strong: 402 alliances were forged during the quarter, well above the recent quarterly average.

In this Decision Resources report, select IPOs, SPOs, debt financings, private placements, venture capital deals, ownership changes, and company alliances are reviewed that occurred during the second quarter of 2005. The report also examines the quarter's most active pharmaceutical and biotechnology companies.

Topics covered include:

- Overview

- Financings

- Ownership Changes

- Alliances

- Most Active Pharmaceutical Companies

- Most Active Biotechnology Companies

For more information visit http://www.researchandmarkets.com/reports/c32213